RNA Methylation Enzyme METTL3 Shields the Aging Ear from Inflammatory Damage

Age-related hearing loss, known medically as presbycusis, is one of the most common sensory deficits of human aging, gradually robbing hundreds of millions of older adults of the ability to follow conversation, enjoy music, and remain connected to the world around them. While hearing aids and cochlear implants can partially compensate, no therapy currently exists that slows or reverses the underlying degeneration of the cochlea. Now, a team of researchers at the Third Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, has uncovered a molecular mechanism that may point toward one. Writing in the Journal of Molecular Medicine, Jingqian Tan, Jia Luo, and colleagues report that an RNA-modifying enzyme called METTL3 acts as a natural brake on the chronic inflammation that drives cochlear aging, and that restoring its activity in aging mice measurably improves hearing.

The study focuses on a chemical tag known as N6-methyladenosine, or m6A, the most abundant internal modification found in messenger RNA. m6A marks are deposited by a family of writer enzymes, of which METTL3 is the principal methyltransferase, and they influence nearly every stage of an RNA molecule’s life, from processing and export to translation and decay. Because m6A modification has already been implicated in a wide range of aging-related diseases, the Chinese team reasoned that it might also play a role in the cochlea, where aging is accompanied by a slow-burning inflammatory state often described as inflammaging. What they found was a strikingly specific protective circuit linking RNA chemistry to the immune response.

To model the disease, the researchers used twelve-month-old C57BL/6 mice, a strain in which hearing loss develops predictably with age, and an in vitro system in which HEI-OC1 auditory cells were stressed with lipopolysaccharide, a bacterial inflammatory trigger, and D-galactose, a sugar that induces senescence-like damage in cells. Auditory function was quantified using auditory brainstem response testing, which measures how effectively the auditory nerve relays sound signals to the brain, while cochlear structure was examined with hematoxylin-eosin staining. Inflammatory signaling was tracked with enzyme-linked immunosorbent assays, quantitative PCR, Western blotting, and immunofluorescence, giving the team a multi-layered picture of gene expression, protein abundance, and cellular localization.

The first key observation was that two molecules were significantly depleted in the cochleae of the aging mice: METTL3 itself, and NFKBIA, the gene encoding nuclear factor-kappaB inhibitor alpha, the protein that keeps the master inflammatory transcription factor NF-κB locked in an inactive state. NF-κB is a central switch in the immune system; when it is released from its inhibitor, it enters the nucleus and switches on a battery of pro-inflammatory genes, including interleukin-6 and components of the NLRP3 inflammasome, a multiprotein complex that drives a highly destructive form of inflammatory cell death called pyroptosis. With NFKBIA levels falling in the aged cochlea, this braking system weakens, allowing the NF-κB/IL-6/STAT3 axis and the NLRP3 inflammasome to fire unchecked.

The team then tested what happens when each component is manipulated. In HEI-OC1 cells, overexpressing NFKBIA suppressed both the NLRP3 inflammasome and the pro-inflammatory NF-κB/IL-6/STAT3 cascade, confirming that this inhibitor acts as a genuine gatekeeper of cochlear inflammation. Conversely, when the researchers boosted METTL3, NF-κB-mediated inflammation subsided, but that protective effect was largely abolished when NFKBIA was knocked down with silencing techniques. This dependency revealed the order of operations: METTL3 does not calm inflammation directly; it does so by keeping NFKBIA abundant, and NFKBIA in turn restrains NF-κB and everything downstream of it.

The mechanistic core of the paper lies in how METTL3 sustains NFKBIA. Using RNA immunoprecipitation combined with quantitative PCR, the researchers showed that METTL3 physically binds to NFKBIA messenger RNA. Using an m6A RNA methylation quantification kit and RNA stability assays, they demonstrated that this binding deposits m6A marks on the transcript and thereby enhances its stability, meaning the message survives longer in the cell and yields more of the inhibitory protein. In other words, METTL3 protects hearing not by changing the genome, but by chemically tuning how long a single anti-inflammatory message persists, a subtle epitranscriptomic intervention with outsized consequences for the inflammatory state of the inner ear.

The decisive experiment came in living animals. When the researchers overexpressed METTL3 in the ARHL mice, NFKBIA levels in the cochlea were restored, auditory brainstem response thresholds improved, and cochlear pathology visible under the microscope was ameliorated. At the molecular level, activation of the NLRP3 inflammasome and the NF-κB/IL-6/STAT3 pathway was suppressed, along with the downstream pyroptotic machinery marked by the gasdermin D-N domain. Taken together, the results trace a complete causal chain from an RNA methyltransferase, through m6A modification of a specific transcript, through a stabilized inhibitor of NF-κB, to reduced inflammatory signaling, preserved cochlear architecture, and better hearing in aged animals.

The significance of this work extends beyond otolaryngology. Chronic low-grade inflammation is now recognized as a shared driver of many age-related conditions, from cardiovascular disease to diabetes and neurodegeneration, and the NF-κB/IL-6/STAT3/NLRP3 axis identified here is a recurring motif across those disorders. Prior studies have shown that m6A modification maintains epithelial homeostasis in the colon through NF-κB signaling, and that other m6A regulators such as ALKBH5 can relieve neuroinflammation by increasing NFKBIA. The new findings place the aging cochlea squarely within this emerging framework, and they suggest that epitranscriptomic therapies, designed to adjust RNA methylation patterns rather than DNA sequences, could offer a way to dampen inflammaging in vulnerable tissues with considerable precision.

Important caveats remain before such a therapy could reach patients. The mouse model, while standard for presbycusis research, does not capture the full complexity of human hearing loss, which is shaped by genetics, noise exposure, vascular health, and lifestyle. Delivering METTL3 or its mRNA to the delicate structures of the inner ear poses formidable technical challenges, and globally enhancing m6A modification carries risks, since the same marks regulate thousands of transcripts, including some involved in cancer and immune function. The authors note that the datasets used in the study are available from the corresponding author on reasonable request, and the work was supported by the National Natural Science Foundation of China and a clinical research program of the Third Affiliated Hospital of Sun Yat-sen University.

Even so, the study offers something the field has lacked: a concrete, mechanistically validated molecular target for a condition long considered an inevitable consequence of growing old. If future work confirms that boosting METTL3 activity, or mimicking its effect on NFKBIA, is safe and feasible in humans, the era of treating age-related hearing loss with drugs rather than devices may come one step closer. For now, the message from Guangzhou is a compelling one: the difference between an aging ear that fails and one that endures may lie, in part, in a single methyl group attached to a single strand of messenger RNA.

Subject of Research: The role of METTL3-mediated m6A modification of NFKBIA in suppressing NF-κB-mediated inflammation in age-related hearing loss

Article Title: METTL3 mitigates age-related hearing loss by inhibiting NF-κB-mediated inflammatory responses through the m6A modification of NFKBIA

Article References: Tan, J., Luo, J., Li, L., Chen, D., Wang, J., Ge, C., & Li, P. (2026). METTL3 mitigates age-related hearing loss by inhibiting NF-κB-mediated inflammatory responses through the m6A modification of NFKBIA. Journal of Molecular Medicine, 104(1), Article 107. https://doi.org/10.1007/s00109-026-02714-5

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02714-5

Keywords: age-related hearing loss, METTL3, NFKBIA, m6A modification, NF-κB, NLRP3 inflammasome, inflammaging, cochlea, RNA methylation, IL-6, STAT3, presbycusis